MetaCap

Rein Therapeutics Inc. (RNTX)

NASDAQ: RNTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.3369-0.0308 (-8.38%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RNTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$29.06M
EPS (TTM)
-$1.51
52-week range
0.284 – 2.10
Day range
0.3352 – 0.3899
Volume / Avg
668.57K / 586.68K
Beta
—

52-week range

$0.284$2.10

RNTX stock today

Rein Therapeutics (RNTX) closed at $0.3369 on Nov 20, down 8.38% (-$0.0308), versus the S&P 500's 3.70% decline. At this level, RNTX sits near the bottom of its 52-week range of $0.284 to $2.10: 84.0% below the high, set on Apr 22, 2026 and 18.6% above the low. RNTX is down 71.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 77.2%.

Rein Therapeutics has posted a net loss over the last twelve months (EPS of -$1.51), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Rein Therapeutics

Company profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. James Brian Windsor Ph.D.
Headquarters
Austin, TX
Employees
10
IPO year
2017
Website
reintx.com

Financial highlights

Full financials

In fiscal 2025, Rein Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Rein Therapeutics reported a net loss of $49.9 million, compared with a loss of $62.9 million a year earlier. Diluted earnings per share came in at -$1.96.

Rein Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0$0$0$0
Growth—————
Net income$-49.87M$-62.88M$-15.73M$-27.33M$-26.16M
EPS (diluted)$-1.96$-3.51$-3.42$-6.02$-5.89

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$6.00+1680.94%

  • Strong buy 1
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.06 vs $-0.10
Surprise
+40.00%

RNTX news

All RNTX news

Rein Therapeutics peers

Health Care sector
RNTX peer companies
CompanyPrice% ChgMarket capCompare
ATHEAlterity Therapeutics Limited ADR1.52-8.16%$29.02Mvs RNTX
NNVCNanoViricides Inc.1.14-2.56%$29.13Mvs RNTX
AYTUAytu BioPharma Inc.2.660.00%$28.91Mvs RNTX
NXTCNextCure Inc.6.45-4.87%$29.53Mvs RNTX
PMNProMIS Neurosciences Inc.3.16-1.56%$28.43Mvs RNTX
SERSerina Therapeutics Inc.1.12-6.67%$29.76Mvs RNTX
EDSAEdesa Biotech Inc.2.00-8.05%$27.02Mvs RNTX
NSRXNasus Pharma Ltd.2.29-10.20%$26.82Mvs RNTX

Indexes, lists and sector

Rein Therapeutics stock FAQ

What is Rein Therapeutics's stock price today?

RNTX last traded at $0.3369 as of Nov 20, 4:00 PM EST, down 8.38% on the day. Prices are delayed at least 15 minutes.

Does Rein Therapeutics pay a dividend?

No. Rein Therapeutics does not currently pay a regular cash dividend.

Who is Rein Therapeutics's CEO?

Dr. James Brian Windsor Ph.D. is the chief executive officer of Rein Therapeutics Inc., which has about 10 employees.

Has RNTX ever split its stock?

Yes. The most recent RNTX stock split was a 1-for-20 split on Nov 11, 2022.

What is the RNTX 52-week high?

The 52-week high for RNTX is $2.10 and the 52-week low is $0.284. The stock is currently 84.0% below its high.

Compare RNTX